Heloise Cheruvalath speaks to ecancer about a study she presented at ASH 2024 into the effects of intravenous immunoglobulin supplementation (IVIG) on infections in recipients of teclistamab therapy for multiple myeloma.

She explains that while bispecific antibodies such as teclistamab are clinically effective, they can cause severe side effects. IVIG supplementation has been shown to prevent such complications but there has been a lack of evidence on the timing of administration.

She reports that the majority of patients ended up being hospitalised due to complications but that 10 out of 11 of the most serious infections were in the group that did not receive primary IVIG.